Q-omics provides the consensus-scored MDK profile across patient tissues and cancer cell-line models. MDK expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MDK is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, MDK protein abundance shows 18,094 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, THCA, and PDAC as cancer lineages where MDK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MDK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MDK survival associations across molecular data types. MDK RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MDK RNA expression–survival associations across cancer types. High MDK expression shows unfavorable associations in KIRC, MESO, UVM, LIHC and ACC, but favorable associations in KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MDK RNA expression.
This table summarizes MDK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MDK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MDK shows higher tumor expression in THCA, KIRC, COAD, LIHC, LUAD and STAD. The THCA box plot shows higher MDK RNA expression in tumor versus normal tissue (log2 FC = +2.750, t-test p < 0.001).
This table shows molecular features associated with MDK in patient tissues and cancer cell lines. In patient samples, MDK shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, MDK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
